KRIBIOLISA™ Glofitamab ELISA
ELISA for the detection of Glofitamab in human serum and plasma. Lead time for this kit is 5 weeks. About the kit: - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life: 1 year
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
